Evidence map›Paper›PMID 38606479›Full record

ArticleActa biochimica et biophysica Sinica2024

Prostate cancer-associated transcript 6 (PCAT6) promotes epithelial-mesenchymal transition and stemness and worsens prognosis in patients with colorectal cancer.

Xun Sun, Yitao Yuan, Suyao Li, Lu Gan, Midie Xu, Qingguo Li, Mengling Liu, Keshu Hu, Ke Nan, Jiayu Zhang and 5 more

Open access · diamondAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Acta biochimica et biophysica Sinica, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
0.3field-weighted citation impact, top 44% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 1 citations in OpenAlex.

  1. Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors at 6 institutions in 1 country.

Xun SunDepartment of Medical Oncology, Zhongshan Hospital, Fudan University, Shanghai 200032, China.
Yitao YuanDepartment of Medical Oncology, Zhongshan Hospital, Fudan University, Shanghai 200032, China.
Suyao LiDepartment of Medical Oncology, Zhongshan Hospital, Fudan University, Shanghai 200032, China.
Lu GanDepartment of Medical Oncology, Zhongshan Hospital, Fudan University, Shanghai 200032, China.
Midie XuDepartment of Pathology and Tissue Bank, Fudan University Shanghai Cancer Center, Shanghai, 200032, China.
Qingguo LiDepartment of Colorectal Surgery, Fudan University Shanghai Cancer Center, Shanghai, 200032, China.
Mengling LiuDepartment of Medical Oncology, Zhongshan Hospital, Fudan University, Shanghai 200032, China.
Keshu HuDepartment of Medical Oncology, Zhongshan Hospital, Fudan University, Shanghai 200032, China.
Ke NanDepartment of Anesthesiology, Zhongshan Hospital, Fudan University, Shanghai 200032, China.
Jiayu ZhangDepartment of Medical Oncology, Zhongshan Hospital, Fudan University, Shanghai 200032, China.
Yu DongDepartment of Medical Oncology, Zhongshan Hospital, Fudan University, Shanghai 200032, China.
Yufu LinDepartment of Oncology, Zhongshan Hospital (Xiamen), Fudan University, Xiamen 361015, China.
Xiuping ZhangXiamen Clinical Research Center for Cancer Therapy, Xiamen Branch, Zhongshan Hospital, Fudan University, Xiamen 361015, China.
Pengcong HouDepartment of Medical Oncology, Zhongshan Hospital, Fudan University, Shanghai 200032, China.
Tianshu LiuDepartment of Medical Oncology, Zhongshan Hospital, Fudan University, Shanghai 200032, China.
Zhongshan Hospital · CNFudan University · CNShanghai Jiao Tong University · CNShanghai Medical College of Fudan University · CNSun Yat-sen University · CNThe First Affiliated Hospital, Sun Yat-sen University · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Approximately 20% of colorectal cancer (CRC) patients are first diagnosed with metastatic colorectal cancer (mCRC) because they develop symptoms at an advanced stage. Despite advancements in treatment, patients with metastatic disease still experience inferior survival rates. Our objective is to investigate the association between long noncoding RNAs (lncRNAs) and prognosis and to explore their role in mCRC. In this study, we find that elevated expression of PCAT6 is independently linked to unfavourable survival outcomes in The Cancer Genome Atlas (TCGA) data, and this finding is further confirmed in CRC samples obtained from Fudan University Shanghai Cancer Center. Cell lines and xenograft mouse models are used to examine the impact of PCAT6 on tumor metastasis. Knockdown of

Indexed as

Colorectal NeoplasmsEpithelial-Mesenchymal TransitionNeoplastic Stem CellsRNA, Long NoncodingAnimalsBiomarkers, TumorCell Line, TumorFemaleGene Expression Regulation, NeoplasticHumansMaleMiceMice, NudePrognosisRNA, UntranslatedBiomarkers, TumorRNA, Long NoncodingRNA, Untranslatedcolorectal cancerlncRNAmetastasisPCAT6

Identifiers

PMID38606479
PMCPMC11214952
OpenAlexW4392657443

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.